Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Monogram Biosciences Announces 4Q 2008 Financial Results


Published on

Monogram Biosciences Announces 4Q 2008 Financial Results

Published in: Economy & Finance
  • Be the first to comment

  • Be the first to like this

Monogram Biosciences Announces 4Q 2008 Financial Results

  1. 1. Monogram Biosciences Announces Fourth Quarter 2008 Financial Results Conference Call SOUTH SAN FRANCISCO, Calif., Jan 30, 2009 (BUSINESS WIRE) -- Monogram Biosciences, Inc., (Nasdaq:MGRM) announced that it will hold a conference call on Thursday, February 12, 2009 at 4:30 p.m. (Eastern Time) to discuss fourth quarter 2008 financial results. The call will be hosted by Mr. William D. Young, Chairman and CEO of Monogram. To participate in the live teleconference, please call (877) 719-9796, or (719) 325-4801 for international callers, fifteen minutes before the conference begins. Live audio of the call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. Following the live broadcast, a replay of the call will also be available beginning at 9:30 p.m. (Eastern Time) at (888) 203-1112, or (719) 457-0820 for international callers, until 11:59 p.m. (Eastern Time) on Sunday, February 22, 2009. The replay passcode is 9724774. Access to live and archived audio of the conference call will be available by following the appropriate links at and clicking on the Investor Relations link. The information provided on the teleconference is only accurate at the time of the conference call, and Monogram will take no responsibility for providing updated information except as required by law. About Monogram Biosciences, Inc. Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at SOURCE: Monogram Biosciences, Inc. Monogram Biosciences, Inc. Alfred G. Merriweather, 650-624-4576 Chief Financial Officer or Feinstein Kean Healthcare Jeremiah Hall, 415-677-2700 Copyright Business Wire 2009